中广核技(000881) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,061,168,449.85, a decrease of 18.98% compared to ¥1,309,795,211.41 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥65,050,648.40, showing a slight improvement of 0.20% from a loss of ¥65,181,223.29 in the previous year[5]. - Net profit for the period was a loss of ¥65,822,026.06, compared to a loss of ¥62,597,662.69 in the previous period, indicating a worsening of approximately 4%[21]. - Total operating revenue decreased to ¥1,061,168,449.85 from ¥1,309,795,211.41, representing a decline of approximately 19% year-over-year[20]. - Total operating costs decreased to ¥1,144,000,244.83 from ¥1,397,561,395.19, a reduction of about 18% year-over-year[20]. Cash Flow - The net cash flow from operating activities improved by 15.92%, amounting to a loss of ¥31,986,734.41 compared to a loss of ¥38,042,141.21 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of ¥31,986,734.41, an improvement from the previous outflow of ¥38,042,141.21[23]. - The cash inflow from operating activities totaled ¥1,286,802,573.45, down from ¥1,494,279,905.78, reflecting a decrease of approximately 14%[23]. - The company reported a 100% decrease in cash received from investment activities, totaling ¥0, as no financial products were invested during the period[11]. - Net cash flow from investing activities was -$80.43 million, compared to -$78.68 million in the previous period[24]. - Cash inflow from financing activities totaled $792.91 million, an increase from $769.28 million year-over-year[24]. - Cash outflow for financing activities was $720.36 million, up from $587.76 million in the prior period[24]. - Net cash flow from financing activities was $72.55 million, down from $181.52 million year-over-year[24]. - The net increase in cash and cash equivalents was -$40.49 million, compared to an increase of $56.62 million in the previous period[24]. - The ending balance of cash and cash equivalents was $1.41 billion, down from $1.08 billion year-over-year[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,531,535,935.17, down 1.60% from ¥10,702,263,483.90 at the end of the previous year[5]. - The total liabilities of the company were CNY 5,047,592,003.11, down from CNY 5,153,939,405.01, representing a decrease of about 2.06%[18]. - Current assets decreased from CNY 6,288,748,438.55 to CNY 6,123,112,485.46, reflecting a decline of approximately 2.63%[17]. - The company's cash and cash equivalents stood at CNY 1,444,595,152.03, down from CNY 1,490,786,138.55, indicating a decrease of about 3.09%[17]. - Accounts receivable decreased from CNY 2,185,366,416.81 to CNY 1,998,990,892.90, a reduction of approximately 8.52%[17]. - Short-term borrowings increased from CNY 1,421,274,006.42 to CNY 1,523,354,808.80, an increase of approximately 7.16%[18]. - The company's equity attributable to shareholders decreased by 1.22%, totaling ¥5,166,300,823.27 compared to ¥5,230,122,212.51 at the end of the previous year[5]. - The company reported a total of 6,123,112,485.46 in current assets, which includes inventory valued at CNY 1,157,707,047.69, an increase from CNY 1,077,521,780.98[17]. - The company has a total of 12,083,642.39 in long-term equity investments, slightly down from 12,271,027.06[17]. Shareholder Information - The company has a significant shareholder, China General Nuclear Power Corporation, holding 28.67% of the shares[15]. Other Financial Metrics - Financial expenses decreased by 51.55% to ¥11,285,475.09, mainly due to increased interest income and exchange gains[10]. - The cash received from tax refunds increased by 80.27% to ¥37,710,701.54, primarily due to an increase in VAT refunds related to medical business[11]. - Research and development expenses decreased to ¥34,383,142.51 from ¥42,425,323.66, a reduction of about 19% year-over-year[20]. - Other comprehensive income after tax increased to ¥1,063,100.31 from ¥158,922.00, showing significant improvement[21]. - The company reported a basic and diluted earnings per share of -0.0688, consistent with the previous period's -0.0689[22]. - The company recorded an investment loss of ¥1,088,206.47, contrasting with a gain of ¥1,879,918.37 in the previous period[20]. Accounting and Reporting - The company has not audited its first-quarter report[25]. - The new accounting standards will be implemented starting in 2025[26].